EDEN TECH

Their core work

EDEN TECH is a French SME specializing in microfluidic device design and manufacturing, primarily for life sciences and environmental applications. They develop miniaturized lab-on-chip systems for diagnostics (sepsis detection, nucleic acid testing), drug testing (organ-on-a-chip with tissue spheroids), cryopreservation of biological samples, and water purification. Their core business revolves around translating microfluidic technology from research-grade prototypes into scalable, application-ready devices for healthcare, pharma, and environmental monitoring sectors.

What they specialise in

How they've shifted over time

EDEN TECH's entire H2020 activity spans 2019–2021 (project start dates), so the evolution is compressed but visible. Early projects (2019–2020) focused on proving their microfluidic platform across diverse applications — cryopreservation (MCRD), agricultural water systems (WATERAGRI), pathogen detection (IPANEMA), and muscle regeneration (RENOIR). Later projects (2020–2021) show a tightening toward environmental remediation (M3R) and clinical diagnostics (FIT-SEP, SMD-SPH), suggesting a move from broad platform validation toward focused product-oriented domains in health and environment.

EDEN TECH is consolidating from a broad microfluidics platform company toward focused applications in clinical point-of-care diagnostics and environmental water treatment — two areas with clear commercial pathways.

How they like to work

EDEN TECH leads more often than it follows — coordinating 6 of 10 projects, mostly MSCA fellowships where they host researchers working on microfluidic applications. As a participant, they join larger consortia (RENOIR, SmartAge, WATERAGRI) where they contribute their device fabrication expertise. With 60 unique partners across 22 countries, they operate as a specialized technology node that attracts international researchers rather than repeatedly collaborating with the same groups.

EDEN TECH has built a broad international network of 60 partners across 22 countries, largely through hosting MSCA fellows from diverse institutions. Their network is wide rather than deep, reflecting their role as a microfluidics hub that attracts researchers from multiple disciplines.

What sets them apart

EDEN TECH occupies a distinctive niche as a microfluidics-specialized SME that bridges the gap between academic research and scalable device production. Unlike university labs that develop one-off prototypes, they provide a commercial platform (FLEXDYM material technology) that researchers can build upon, making them a natural host for MSCA fellows needing industrial microfluidic capabilities. Their ability to apply the same core technology across diagnostics, tissue engineering, and environmental monitoring makes them an unusually versatile partner for interdisciplinary consortia.

Highlights from their portfolio

• RENOIR
  Largest single grant (EUR 549,604) and a complex muscle regeneration project combining microfluidics with biomaterials, epigenetics, and live imaging — shows EDEN TECH operating at the frontier of organ-on-chip applications.
• FIT-SEP
  Coordinator of a fully integrated sepsis diagnostic device combining phage display, biological nanoparticles, and point-of-care microfluidics — their most clinically advanced project with direct medical product potential.
• FLEXDYM
  Their SME Phase 1 project to commercialize a new microfluidic material, representing the company's core product ambition and the foundation underlying many of their other projects.